EMA Gets Tough on Conflicts of Interest - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Gets Tough on Conflicts of Interest


ePT--the Electronic Newsletter of Pharmaceutical Technology

The Management Board of the European Medicines Agency (EMA) has introduced a range of new measures to strengthen and extend its conflicts of interest (COI) policy for scientific-committee members and experts, as well as for members of the management board.

Taking into account the last 6 months’ experience, the EMA's policy include measures to clarify involvement in academic trials and publically funded R&D initiatives, as well as to align risk and related restrictions for the different roles in the scientific decision process and to tighten rules on grants from the pharmaceutical industry. The new policy also outlines specific restrictions for board members, such as preventing members from participating in discussions and decision making.

Additional measures to support quality assurance were also agreed upon, including the introduction of a breach of trust procedure for incomplete or incorrect declarations of interest and retrospective cross-checking of COI declarations and risk-mitigation measures.

The new policy enters into force immediately and replaces the previous rules, which had been in effect since September 2011.

“Since taking up the leadership of the European Medicines Agency in November, one of my main focuses has been on strengthening the ways the Agency deals with conflicts of interests and transparency,” the Agency’s executive director Guido Rasi said in a statement. “These issues will continue to be a major focus of the Agency’s work over the months and years to come.”

Transparency

In a press statement released last week about the new policy, the agency also reported on initiatives to improve transparency. In response to the Europe’s new pharmacovigilance legislation, which will have a significant impact on transparency issues for national authorities, the EMA will enhance the transparency of its processes and procedures by:

  • Publishing agendas, recommendations, opinions, and minutes from its scientific committees, including the Pharmacovigilance and Risk Assessment Committee (PRAC), the human medicines Coordination Group, and the Committee for Medicinal Products for Human Use
  • Engaging with the public on safety issues through public hearings, simultaneously ensuring consistent safety messages across Europe
  • Preparing a paper on rules of procedure for the organization and conduct of public hearings. The paper will be discussed by PRAC at its inaugural meeting on July 19–20, 2012.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here